AQR Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

AQR Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-23,680	Closed	-$83K	–	2275
2018 Q4	$83K	Buy	+23,680	New	+$165K	﹤0.01%	2158
2016 Q1	–	Sell	-34,319	Closed	-$983K	–	2328
2015 Q4	$983K	Sell	34,319 -22,888	-40%	-$634K	﹤0.01%	1581
2015 Q3	$1.63M	Sell	57,207 -3,288	-5%	-$121K	﹤0.01%	1223
2015 Q2	$2.17M	Buy	60,495 +9,893	+20%	+$308K	﹤0.01%	1149
2015 Q1	$1.47M	Sell	50,602 -12,102	-19%	-$320K	﹤0.01%	1247
2014 Q4	$1.32M	Sell	62,704 -16,600	-21%	-$328K	﹤0.01%	1521
2014 Q3	$1.54M	Buy	79,304 +600	+0.8%	+$9.42K	﹤0.01%	1403
2014 Q2	$1.23M	Buy	78,704 +600	+0.8%	+$9.7K	﹤0.01%	1544
2014 Q1	$1.62M	Buy	78,104 +20,714	+36%	+$411K	﹤0.01%	1433
2013 Q4	$741K	Buy	+57,390	New	+$796K	﹤0.01%	1868

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

AQR Capital Management's INSY Position: Q1 2019 in Review

AQR Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 23,680 shares — an estimated $83K sold.

AQR Capital Management first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $2.17M in Q2 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

AQR Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
AQR Capital Management sold 23,680 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $83K.
AQR Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
AQR Capital Management's Insys Therapeutics, Inc. position peaked at $2.17M in Q2 2015.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on AQR Capital Management's 13F filing for Q1 2019, filed 14 May 2019.